Study Completed

Neoplasms

Bayer Identifier:

16447

ClinicalTrials.gov Identifier:

NCT01915576

EudraCT Number:

2012-004671-39

EU CT Number:

Not Available

Phase I dose escalation study with an allosteric AKT 1/2 inhibitor in patients

Trial purpose

This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1125976. The relative bioavailability of liquid service formulation and tablets will be determined.
After the MTD is defined breast cancer patients with and without AKT1 mutation will be treated.
The study will also assess the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of BAY1125976.
BAY1125976 will be given daily as single oral application. Treatment will be stopped if the tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the patient decides to exit treatment.

Key Participants Requirements

Sex

Both

Age

18 - N/A

Inclusion Criteria
- For dose escalation cohorts: Subjects with advanced, histologically or cytologically confirmed solid tumors are eligible. Subjects’ tumors (all comers) must be refractory to standard treatment with no standard therapy available, or subjects actively refuse any treatment, which would be regarded standard. In addition, the investigator must judge the experimental treatment as clinically and ethically acceptable
- For expansion cohort only: Subjects with histologically or cytologically proven metastatic breast cancer (with and without AKT1 E17K (G49A) mutation) or subjects with known AKT1 E17K (G49A) mutation in any other advanced solid tumor with at least one line of chemotherapy in the metastatic setting and not amenable to surgery with curative intent
- Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 – 2
- Bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within 7 days prior to starting study treatment
- Subjects must provide tumor biopsies before treatment
- Recovery to CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade 0 or Grade 1 or recovery to baseline preceding the prior treatment of any previous drug / procedure-related toxicity (except alopecia, anemia, and hypothyroidism)
Exclusion Criteria
- History of cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II
- Subjects with type 1 or type 2 diabetes mellitus
- Subjects with fasting glucose >125 mg/dL in 2 independent measurements or glycated hemoglobin (HbA1c) ≥ 7%
- Moderate and severe hepatic impairment, i.e. Child-Pugh B or C
- Active infections of CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade >2 or infections of CTCAE Grade 2 not responding to therapy
- Symptomatic metastatic brain or meningeal tumors unless the patient is > 3 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.
- Subjects undergoing renal dialysis
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1) or any cancer curatively treated > 3 years prior to study entry
- Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
- Treatment with oral steroids (dose ≥ 10 mg/day of methylprednisolone or equivalent)
- Clinically relevant findings in the ECG such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec
- Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized to CTCAE Grade equal or lower than 1 (excluding alopecia)

Trial summary

Enrollment Goal

Trial Dates

September 2013 - December 2016

Phase

Phase 1

Could I Receive a placebo

Products

BAY1125976

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Completed		Heidelberg, 69120, Germany
Completed		St. Gallen, 9007, Switzerland
Completed		Houston, 77030, United States
Completed		Santa Monica, 90404, United States
Completed		VILLEJUIF CEDEX, 94805, France
Completed		St. Louis, 63110, United States
Completed		Boston, 02215, United States

Primary Outcome

Number of participants with adverse events as a measure of safety and tolerability
Time Frame:
up to 2 years
Safety Issue:
Yes
Maximum tolerated dose (MTD) of BAY1125976
Time Frame:
up to 2 years
Safety Issue:
Yes
Area under the plasma concentration vs time curve from zero to infinity after single (first) dose
Time Frame:
at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post-dose
Safety Issue:
No

Secondary Outcome

Food effect assessment
The effect of a high-fat, high-calorie meal on the pharmacokinetic parameters of BAY1125976 will be determined in 6 – 9 subjects in the MTD dose level or a lower dose level receiving the tablet for the cohort of the dose escalation part.
Time Frame:
up to 2 years
Safety Issue:
No
Tumor response will be evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions
Time Frame:
up to 2 years
Safety Issue:
No

Trial design

A Phase I, multi-center, non-randomized, open-label, dose escalation design study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1125976 in subjects with advanced solid tumors

Trial Type

Interventional

Intervention Type

Drug

Trial Purpose

Treatment

Allocation

Non-randomized

Blinding

Open Label

Assignment

Single Group Assignment

Trial Arms

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.